Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Notice of Extraordinary General Meeting of NeuroVive Pharmaceutical AB (publ)

The shareholders of NeuroVive Pharmaceutical AB (publ), 556595-6538, are hereby convened to the Extraordinary General Meeting, held at 2 pm on Thursday 22 March 2018 at Medicon Village, Scheelevägen 2, in Lund, Sweden.Entitlement to participate and notification Shareholders that wish to participate at the Extraordinary General Meeting should: · be included in the share register maintained by Euroclear Sweden AB on Friday 16 March 2018, and · notify the company by email to anmalan@neurovive.com or, in writing to NeuroVive Pharmaceutical AB, Medicon Village, Scheelevägen 2, 223 81

Metsä Tissue invests in new Away-from-Home production line in Raubach mill

Metsä Tissue is investing in a new production line for hand towels in its Raubach mill in Germany. The total investment is approximately EUR 10 million and the new production line for Away-from-Home products will be operative by the end of 2018. “The demand for tissue papers is expected to continue steady in all market areas. With this investment we want to strengthen our capacity and market position especially in the West European Away-from-Home markets. Raubach mill is conveniently located for serving the Continental customers, and with this investment, we can ensure prompt deliveries

Receipt of payment for KRI oil exports

15 February 2018 Genel Energy plc Receipt of payment for KRI oil exports Genel Energy plc (‘Genel’) announces that the Taq Taq partners have received a gross payment of $11.05 million from the Kurdistan Regional Government (‘KRG’) for oil sales during November 2017. Genel’s net share of the payment is $6.08 million. Genel also notes the announcement from DNO ASA, as operator of the Tawke PSC, that the Tawke partners have received $54.73 million from the KRG as payment for November 2017 crude oil deliveries to the export market from the Tawke licence. Genel's net share of the

Skandia and GHP expand collaboration for better care

Skandia and GHP already have collaboration regarding insurance customers in Stockholm with orthopaedic and spine injuries where the focus is on securing and maintaining the care chain for customers. This collaboration is now being expanded to also include customers in Gothenburg with these injuries.Health care in Sweden is far too fragmented and there is too little focus on the actual results of the care given. Closer cooperation with coherent and well-considered care chains can achieve higher quality and better use of the health care service’s resources. Skandia and GHP already have this

Year-end report 1 January - 31 December 2017

FOURTH QUARTER (OCTOBER-DECEMBER 2017) ·  Other operating income amounted to KSEK 0 (0) ·  Operating loss totalled KSEK -7,289 (-4,255) ·  Loss for the period totalled KSEK -7,315 (-4,255) ·  Cash flow from operating activities was KSEK -8,250 (-3,035) ·  Loss per share before dilution was SEK 0.35 (-0.36). Loss per share after dilution was SEK 0.19 (-0.36) ·  The proposed dividend is SEK 0.00/share (0.00) ·  This fourth quarter/year-end report has been prepared in accordance with RFR 2, Accounting for Legal Entities. The report has been prepared in accordance with

Båstad-Gruppen is growing – ChromoGenics’ dynamic glass ConverLight® selected when the facility in Ängelholm is further expanded.

ChromoGenics AB (publ) has received an order to deliver approximately 20m2 ConverLight® dynamic glass to Båstad-Gruppen in Ängelholm, Sweden, for the expansion of their offices. Peab Byggservice AB is the appointed building contractor for the project.Båstad-Gruppen, one of the leading suppliers of protective and professional shoes and boots in the Nordics with sales across Europe, will end up with a total of approximately 6,000 m2 of warehouse and office space after completing the expansion of its plant in Ängelholm. "We are currently going through an incredible expansion phase and will

NeuroVive decides on a Rights issue for continued drug development

Lund, Sweden, 15 February 2018, NeuroVive Pharmaceutical AB (publ) (Nasdaq Stockholm: NVP, OTCQX: NEVPF) announces that the Board of Directors of NeuroVive Pharmaceutical AB (publ) ("NeuroVive" or "the Company") on 15 February 2018 resolved, subject to approval by the Extraordinary General Meeting, to issue shares and warrants with preferential rights for existing shareholders ("Rights issue"). Upon full subscription to the Rights issue, the Company will receive approximately MSEK 78.5 before issuance costs. In full exercise of the warrants issued in the Rights issue, the Company will receive

Year-end report 2017

NET ASSET VALUE AND THE LATOUR SHARE ·The net asset value rose to SEK 95 per share, compared with SEK 87 per share at the beginning of the year. This is an increase of 11.6 per cent, adjusted for dividends. By comparison, the Stockholm Stock Exchange's Total Return Index (SIXRX) increased by 9.5 per cent. The net asset value was SEK 93 per share at 14 February. (1) ·The total return on the Latour share was 20.3 per cent during the year compared with 9.5 per cent for the SIXRX. ·The Board of Directors proposes that the dividend be increased to SEK 2.25 (2.00) per share.

Andreas Ivarsson — new Director of Projects & Developments at Wihlborgs

Wihlborgs’ Director of Projects & Developments Ulrika Hallengren is to take over the role as CEO of Wihlborgs when Anders Jarl is proposed as Chairman. In conjunction with this, Andreas Ivarsson will become the new Director of Projects & Developments.Andreas Ivarsson has been working as a property developer at Wihlborgs since August 2017. He joined Wihlborgs from a position as Area Manager for Skandia Fastigheter. Andreas worked at Skandia for eleven years where his duties included driving the Masthusen development in the Västra hamnen district of Malmö — an extensive urban regeneration

Promore Pharma Regains Rights for PXL01 Manufacturing

STOCKHOLM, SWEDEN, February 15, 2018 –  Promore Pharma AB, a Swedish biopharmaceutical developer of therapeutic peptides, today announced that it will assume responsibility for the manufacturing of the investigational medicinal product for the clinical Phase III trial for PXL01 and at the same time, the company regains the global manufacturing rights for the commercial product.In March 2016, Promore Pharma entered into an agreement with PharmaResearch Products Ltd ("PRP") regarding development collaboration on PXL01, complemented by a manufacturing agreement in January 2017. In accordance

Dow BioMedica to distribute Biohit GastroPanel® in Korea

Biohit Oyj Press release, 15[th] February, 2018 at 9.30 a.m. local time (EET) Biohit Oyj and Dow BioMedica have signed an agreement for the distribution of Biohit GastroPanel in Korea. The contract has been signed for four years with a continuation option. The registration will start during the 1[st] quarter of 2018. CEO Young Gill Shin, Dow BioMedica Inc.: “Korea has high incidence of Helicobacter pylori infection caused atrophic gastritis and related risks such as gastric cancer. GastroPanel as a primary examination will find patients for further examination, and allows more cost-

Selumetinib in NF1 gets FDA orphan drug status

15 February 2018 07:00 GMT SELUMETINIB GRANTED ORPHAN DRUG DESIGNATION BY THE US FDA FOR NEUROFIBROMATOSIS TYPE 1 AstraZeneca and Merck & Co., Inc., Kenilworth, NJ, US (known as MSD outside the US and Canada) today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for selumetinib, a MEK 1/2 inhibitor, for the treatment of neurofibromatosis type 1 (NF1). NF1 is an incurable genetic condition that affects one in 3,000 births,[i]  with highly-variable symptoms, including cutaneous (skin), neurological (nervous system) and

Aspire Global Year-end report 2017

A strong fourth quarter led to record numbers in both revenue and EBITDA for the full year 2017Fourth quarter (Oct-Dec 2017) · Revenues increased by 27% to MEUR 19.2 (15.1) · B2B Revenues increased by 40% to MEUR 10.3 (7.3) · EBITDA increased by 35% to MEUR 3.8 (2.8) · EBITDA margin increased to 20% (19%) · EBIT increased by 33% to MEUR 3.5 (2.6) · Earnings after tax amounted to MEUR 3.3 (3.7) · Basic earnings per share*, after tax, from continued   operations amounted to EUR 0.03 (0.09) · First Time Depositors (FTDs) increased by 55% to 68.0 thousand (43.8)

REG Power Management Selects Greenbyte for Data Management

REG Power Management has selected Greenbyte’s modern software systems Breeze for wind farm management and Bright for solar PV plant management.REG Power Management, headquartered in Guildford UK, is a developer, owner and operator of renewable energy projects, with a track record of over 1000 MW. Greenbyte will work with REG Power Management to bring into Breeze and Bright their current portfolio of 30 wind farms and 10 solar PV plants. The systems will be used for real time production monitoring, streamlined reporting and in-depth data analysis over any time period to optimize plant energy

Bank of Lithuania issues inspection findings on Swedbank

During autumn 2017, the Bank of Lithuania has carried out an inspection related to Swedbank’s activities in the area of money laundering and terrorism financing prevention (AML/CTF) for the period January 2016 until March 2017.The findings include deficiencies in internal control systems for money laundering prevention, processes and documentation. Based on the results, Bank of Lithuania issued a warning to Swedbank and obliged to remedy identified deficiencies. -Swedbank takes the findings by Bank of Lithuania very seriously. We would like to emphasize that AML and CTF is a prioritised

Attendo's year-end report 2017 - New record in the number of new nursing homes, the Board has appointed Pertti Karjalainen as acting CEO

Attendo showed a record high number of new beds in nursing homes being established during 2017. Profit for the fourth quarter was in line with the same quarter 2016, but at a lower margin. The number of units under construction remains at a very high level and is laying a foundation for continued stable growth.Comments by Henrik Borelius, CEO “With a record high number of establishments and acquisitions, Attendo sharply increased the number of beds in own operations during the year. At year-end 2017, Attendo had 13,262 beds in own operations, an increase by 43 percent compared to

Clavister Q4 2017: All-time High Quarter and Full Year Revenues

Clavister’s Q4 2017 report shows record revenues and gross profit. Q4 revenues grew to 27% and reached 34.4 MSEK. The full year growth was 28%, reaching all-time annual revenues  over 100 MSEK.February 15, 2018. Örnsköldsvik, Sweden. Clavister (Nasdaq: CLAV), a leader in high-performance network security solutions, released its latest quarterly report showing increases in key metrics including Q4 revenues reaching 34,4 MSEK(+27%), gross margin rose to 77%, and gross profit improved by 31%, year-on-year.For the full year 2017, the revenues rose by 28% and reached, for the first time, over

Summons to the Annual General Meeting of shareholders in Castellum AB (publ)

The shareholders of Castellum AB (publ), Reg. No. 556475-5550, are hereby summoned to the Annual General Meeting to be held on Thursday, March 22, 2018 at 5 pm in RunAn, Chalmers Kårhus, Chalmersplatsen 1, Gothenburg. The entrance opens at 4 pm.Notification etc.Shareholders wishing to attend the Annual General Meeting must be registered as shareholders in the share register kept by Euroclear Sweden AB by Friday, March 16, 2018 and must also have notified their attendance to the company no later than Friday, March 16, 2018 (preferably before 4 pm). Notification of attendance at the

Year-end report January-December 2017

The fourth quarter developed positively for Bong. Stable envelope sales and qrowth in light packaging compared to previous year contributed to a continued improvement in earnings. The milestone of a positive result before tax for the full year was achieved. The cash flow was also strong and this allows for continued investments in light packaging to accelerate Bongs transformation, says Bong’s CEO Håkan Gunnarsson.October – December 2017• Net sales amounted to SEK 578 million (579)• Operating profit before depreciation increased to SEK 29 million (28)• Operating profit increased to

Hexagon announces next generation Leica Rugby lasers – the first upgradable lasers for construction

Hexagon, a leading global provider of information technology solutions, launched today the Leica Rugby CLH and Leica Rugby CLA lasers. This next generation of lasers offer the unique capability to adapt to user application needs through software upgrades – an industry first.With a focus on application flexibility, simplicity and durability, the new Leica Rugby lasers increase productivity and allow for maximum performance as construction projects evolve.These new lasers provide users access to upgrades that extend functionality and adapt to application needs. This ensures users have the

Elos Medtech builds up a strong platform within Dental Implant Systems

Elos Medtech announces that Soren Olesen, Managing Director of Elos Medtech Pinol, will take up a new role as Dental Business Director and lead our global dental implant strategy within one of our important business segments, Dental Implant System. During the years Elos Medtech has evolved a strong global dental offering as development- and manufacturing partner. Specialized expertise within development and manufacturing as well as innovative developed dental instruments and digital dentistry products, is the platform for Elos Medtech’s dental strategy and future growth. Elos Medtech has

Immunovia Full Year report, January-December 2017

“The fourth quarter of 2017 marked an important inflection point for Immunovia in many aspects. We ended our final year of purely pre-commercial activity, and have now started what is planned as our first business year that will lead to the start of sales in the second half of 2018.” “During 2018 we expect to reach our target of starting commercial sales of IMMray™  PanCan –dby providing the test to customers, both private individuals and health organizations, so-calledself-pay customers.” “The internal work aimed at preparing the company for a listing on Nasdaq Stockholm’s main market

Year-end report 2017

Quarter 4, 2017  · Incoming orders amounted to SEK 815.9m (830.5), which organically is a decrease of 0.8 percent compared with the same period last year. · Net sales amounted to SEK 860.0m (820.1), which organically is an increase of 4.9 percent compared with the same period last year. · Adjusted operating profit was SEK 106.8m (85.5), giving an adjusted operating margin of 12.4 percent (10.4). · Operating profit was SEK 99.1m (85.5), giving an operating margin of 11.5 percent (10.4). · Net profit was SEK 73.2m (61.1). · Earnings per share were SEK 6,26 (5,23).

There are no items matching the current filter
There are no more items matching the current filter
Back to top